Suppr超能文献

实验性心脏停搏方法对正常和肥厚大鼠心脏的影响。

Effect of experimental cardioplegia methods on normal and hypertrophied rat hearts.

作者信息

Hochhauser E, Barak Y, Einav S, Cohen S, Vidne B

机构信息

Department of Thoracic and Cardiovascular Surgery, Tel Aviv Medical Center, Ichilov Hospital, Israel.

出版信息

Ann Thorac Surg. 1988 Aug;46(2):208-13. doi: 10.1016/s0003-4975(10)65900-0.

Abstract

The purpose of this study was to evaluate whether the addition of verapamil hydrochloride to oxygenated glucose-rich cardioplegic solution would improve myocardial preservation. The Langendorff preparation of the isolated rat heart was used. Groups of normal (WKY) and hypertrophied (SHR) hearts were treated by five different cardioplegic methods and subjected to 90 or 30 minutes of ischemia at 28 degrees to 29 degrees C and reperfusion at 37 degrees C. The following cardioplegic solutions were used: Group A, cold (16 degrees C) Krebs-Henseleit (KH) glucose free only; Group B, KH with KCL (30 mEq/L) (16 degrees C); Group C, same as B with verapamil (10 microM); Group D, perfusion with oxygenated KH solution containing KCL (30 mEq/L) for 15 minutes prior to ischemia; and Group E, same as D with verapamil (10 microM). Recovery of contraction amplitude, ischemic contracture, coronary perfusate volume, the amount of creatine kinase in the coronary perfusate, heart rate, time of revival, O2 consumption, and ischemic contracture were measured. After 30 minutes of ischemia, we did not find any significant difference among the combinations tested with respect to contraction amplitude recovery. The hearts recovered fully. After 90 minutes of ischemia, we found that the best-protected groups in the normal hearts were Groups D and E. In the hypertrophied hearts, the addition of verapamil to the enhancement solution was harmful. The use of enhancement solution without verapamil prior to ischemia provided the best myocardial protection in the hypertrophied hearts.

摘要

本研究的目的是评估在富含氧合葡萄糖的心脏停搏液中添加盐酸维拉帕米是否能改善心肌保护。采用离体大鼠心脏的Langendorff制备方法。将正常(WKY)和肥大(SHR)心脏分组,用五种不同的心脏停搏方法进行处理,并在28℃至29℃下进行90或30分钟的缺血,然后在37℃下进行再灌注。使用了以下心脏停搏液:A组,冷(16℃)无葡萄糖的Krebs-Henseleit(KH)液;B组,含氯化钾(30 mEq/L)的KH液(16℃);C组,与B组相同,但添加了维拉帕米(10 microM);D组,在缺血前用含氯化钾(30 mEq/L)的氧合KH液灌注15分钟;E组,与D组相同,但添加了维拉帕米(10 microM)。测量收缩幅度恢复、缺血性挛缩、冠状动脉灌注液体积、冠状动脉灌注液中肌酸激酶含量、心率、复苏时间、耗氧量和缺血性挛缩。缺血30分钟后,在所测试的组合中,我们未发现收缩幅度恢复方面有任何显著差异。心脏完全恢复。缺血90分钟后,我们发现正常心脏中保护效果最佳的组是D组和E组。在肥大心脏中,在强化液中添加维拉帕米是有害的。在缺血前使用不含维拉帕米的强化液能为肥大心脏提供最佳的心肌保护。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验